Literature DB >> 23132513

Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients.

Nadezda Petejova1, Arnost Martinek, Jana Zahalkova, Jana Duricova, Hana Brozmannova, Karel Urbanek, Milan Grundmann, Jiri Plasek, Ivana Kacirova.   

Abstract

AIMS: To assess the influence of continuous venovenous hemofiltration (CVVH) at a filtration rate of 45 mL/kg/h on vancomycin pharmacokinetics in critically ill septic patients with acute kidney injury (AKI).
METHODS: Seventeen adult septic patients with acute kidney injury treated with CVVH and vancomycin were included. All patients received first dose of 1.0 g intravenously followed by 1.0 g/12 h if not adjusted. In sixteen patients vancomycin was introduced on the day of the start of CRRT therapy. Blood samples and ultrafiltrates were obtained before and 0.5, 1, 6 and 12 h after vancomycin administration.
RESULTS: On the first day, the median total vancomycin clearance (Cltot) was 0.89 mL/min/kg (range 0.31 - 2.16). CRRT clearance accounted for around 50-60% of the total clearance of vancomycin found in a population with normal renal function (0.97 mL/min/kg). Vancomycin serum concentrations after the first dose were below the required target of 10 mg/L as early as 6 h in 10 patients, AUC0-24/MIC ≥ 400 ratio was achieved in 10 patients on the first day.
CONCLUSIONS: CVVH at a filtration rate of 45 mL/kg/h leads to high and rapid extracorporeal removal of vancomycin in critically ill patients. Due to the rapid change in patient clinical status it was impossible to predict a fixed dosage regimen. We recommend blood sampling as early as 6 h after first vancomycin dose with maintenance dose based on vancomycin serum level monitoring.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23132513     DOI: 10.5507/bp.2012.092

Source DB:  PubMed          Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub        ISSN: 1213-8118            Impact factor:   1.245


  7 in total

Review 1.  Optimizing the Clinical Use of Vancomycin.

Authors:  Rocío Álvarez; Luis E López Cortés; José Molina; José M Cisneros; Jerónimo Pachón
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

2.  Vancomycin therapy in critically ill patients on continuous renal replacement therapy; are we doing enough?

Authors:  Ali S Omrani; Alaa Mously; Marylie P Cabaluna; John Kawas; Mohammed M Albarrak; Wafa A Alfahad
Journal:  Saudi Pharm J       Date:  2014-09-07       Impact factor: 4.330

3.  Development of a vancomycin dosing approach for critically ill patients receiving hybrid hemodialysis using Monte Carlo simulation.

Authors:  Susan J Lewis; Bruce A Mueller
Journal:  SAGE Open Med       Date:  2018-05-11

4.  Factors affecting serum concentration of vancomycin in critically ill oliguric pediatric patients receiving continuous venovenous hemodiafiltration.

Authors:  Bongjin Lee; Soo Jung Kim; June Dong Park; Jiun Park; Ae Hee Jung; Sun Hoi Jung; Yu Hyeon Choi; Hee Gyung Kang; Il Soo Ha; Hae Il Cheong
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

5.  Vancomycin therapeutic drug monitoring in patients on continuous renal replacement therapy: a retrospective study.

Authors:  Yuyan Liu; Li Jiang; Ran Lou; Meiping Wang; Quan Si
Journal:  J Int Med Res       Date:  2022-09       Impact factor: 1.573

Review 6.  Acute Kidney Injury in Septic Patients Treated by Selected Nephrotoxic Antibiotic Agents-Pathophysiology and Biomarkers-A Review.

Authors:  Nadezda Petejova; Arnost Martinek; Josef Zadrazil; Marcela Kanova; Viktor Klementa; Radka Sigutova; Ivana Kacirova; Vladimir Hrabovsky; Zdenek Svagera; David Stejskal
Journal:  Int J Mol Sci       Date:  2020-09-26       Impact factor: 5.923

7.  Case Report: Monitoring Vancomycin Concentrations and Pharmacokinetic Parameters in Continuous Veno-Venous Hemofiltration Patients to Guide Individualized Dosage Regimens: A Case Analysis.

Authors:  Jihui Chen; Xiaohui Huang; Zhiyan Lin; Chao Li; Haoshu Ding; Junming Du; Lixia Li
Journal:  Front Pharmacol       Date:  2021-12-09       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.